Key Highlights

  • bioAffinity Technologies is positioning CyPath Lung as a noninvasive monitoring tool for patients post-curative treatment.
  • The goal is to detect recurrence or secondary primary lung cancers.
  • The company noted high diagnostic accuracy in early-stage detection with a 99% NPV.
  • Current validation data focuses on screening high-risk populations rather than long-term surveillance of surgical survivors.

bioAffinity Technologies, Inc. (NASDAQ: BIAF) is positioning its CyPath Lung test as a noninvasive monitoring tool for patients post-curative treatment to detect recurrence or secondary primary lung cancers.

What Happened

The company noted high diagnostic accuracy in early-stage detection with a 99% negative predictive value, though it cautioned that current validation data focuses on screening high-risk populations rather than long-term surveillance of surgical survivors.

Market Reaction

The disclosed information does not include stock price or trading data for bioAffinity Technologies following this positioning update.

Outlook

Additional validation data specific to long-term surveillance of surgical survivors would be needed to fully support CyPath Lung's use in this new post-treatment monitoring context.